Roth Capital Downgrades Celator Pharma (CPXX) to Neutral Amid Jazz Pharma (JAZZ) Deal
Tweet Send to a Friend
Roth Capital downgrades Clelator Pharma (Nasdaq: CPXX) from Buy to Neutral rating and lifts its price target from $26 to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
